Pharsight

Drugs that contain Cabazitaxel

1. Jevtana Kit patents expiration

JEVTANA KIT's oppositions filed in EPO
JEVTANA KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(1 year, 9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241907

(Pediatric)

SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Jun, 2026

(2 years from now)

US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)

US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(6 years from now)

US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Dec 18, 2023

Market Authorisation Date: 17 June, 2010

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg de...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage

JEVTANA KIT family patents

Family Patents